Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $5.80 and last traded at $6.09, with a volume of 445073 shares trading hands. The stock had previously closed at $6.19.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience currently has an average rating of “Sell”.
Check Out Our Latest Research Report on Regencell Bioscience
Regencell Bioscience Stock Performance
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.
Institutional Investors Weigh In On Regencell Bioscience
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new stake in Regencell Bioscience in the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience during the 2nd quarter valued at $768,000. XTX Topco Ltd bought a new position in shares of Regencell Bioscience during the 3rd quarter valued at $598,000. Hudson Bay Capital Management LP purchased a new position in shares of Regencell Bioscience in the 4th quarter worth $275,000. Finally, Vident Advisory LLC boosted its stake in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares during the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.
About Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
See Also
- Five stocks we like better than Regencell Bioscience
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
